ES2127286T3 - Factor tisular truncado y activador de fviia o fvii para la coagulacion de la sangre. - Google Patents

Factor tisular truncado y activador de fviia o fvii para la coagulacion de la sangre.

Info

Publication number
ES2127286T3
ES2127286T3 ES93913844T ES93913844T ES2127286T3 ES 2127286 T3 ES2127286 T3 ES 2127286T3 ES 93913844 T ES93913844 T ES 93913844T ES 93913844 T ES93913844 T ES 93913844T ES 2127286 T3 ES2127286 T3 ES 2127286T3
Authority
ES
Spain
Prior art keywords
fviia
ttf
activator
factor
viia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93913844T
Other languages
English (en)
Inventor
James H Morrissey
Philip C Comp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/882,202 external-priority patent/US5374617A/en
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of ES2127286T3 publication Critical patent/ES2127286T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE HA DESCUBIERTO QUE ES POSIBLE ADMINISTRAR FACTOR DE TEJIDO TRUNCADO, NO TENIENDO UNA ZONA TRANSMEMBRANA (TTF) EN COMBINACION CON EL FACTOR VIIA (FVIIA) O UN ACTIVADOR DEL FACTOR VII ENDOGENO, PARA TRATAR TRASTORNOS SANGRANTES TALES COMO LOS QUE SE PRODUCEN EN LA HEMOFILIA O CIRROSIS DEL HIGADO. EL TTF SE ADMINISTRA PARA OBTENER HASTA 10 (MU)G TTF/ML DE PLASMA. EL ACTIVADOR FVIIA O FVII SE ADMINISTRA PARA OBTENER NIVELES ENTRE 40 (MU)G VIIA/ML Y 700 (MU)G FVIIA/ML DE PLASMA. LAS DOSIS EFICACES DE AMBOS TTF Y ACTIVADOR VII DE VIIA/FACTOR SON SIGNIFICATIVA Y SORPRENDENTEMENTE INFERIORES A LA ADMINISTRACION DE CUALQUIERA DE ELLOS AISLADO PARA DETENER LA SANGRADURA. EJEMPLOS DEMUESTRAN LA SEGURIDAD Y EFICACIA EN PERROS NORMALES Y HEMOFILICOS.
ES93913844T 1992-05-13 1993-05-12 Factor tisular truncado y activador de fviia o fvii para la coagulacion de la sangre. Expired - Lifetime ES2127286T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/882,202 US5374617A (en) 1992-05-13 1992-05-13 Treatment of bleeding with modified tissue factor in combination with FVIIa
US08/021,615 US5504064A (en) 1991-04-10 1993-02-19 Treatment of bleeding with modified tissue factor in combination with an activator of FVII

Publications (1)

Publication Number Publication Date
ES2127286T3 true ES2127286T3 (es) 1999-04-16

Family

ID=26694897

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93913844T Expired - Lifetime ES2127286T3 (es) 1992-05-13 1993-05-12 Factor tisular truncado y activador de fviia o fvii para la coagulacion de la sangre.

Country Status (10)

Country Link
US (1) US5504064A (es)
EP (1) EP0642352B1 (es)
JP (1) JP3663550B2 (es)
AT (1) ATE175876T1 (es)
AU (1) AU676168B2 (es)
CA (1) CA2134750C (es)
DE (1) DE69323195T2 (es)
DK (1) DK0642352T3 (es)
ES (1) ES2127286T3 (es)
WO (1) WO1993023074A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
DE4416180C2 (de) * 1994-05-06 1997-08-14 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats
US6017891A (en) * 1994-05-06 2000-01-25 Baxter Aktiengesellschaft Stable preparation for the treatment of blood coagulation disorders
CA2194369C (en) * 1994-07-11 2004-08-31 Philip E. Thorpe Methods and compositions for the specific coagulation of vasculature
EP0862742B1 (en) * 1995-11-22 2003-06-11 Oklahoma Medical Research Foundation Assay for blood clotting factors viii and ix
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
IL130908A0 (en) * 1997-01-22 2001-01-28 Univ Texas Tissue-factor (tf) compositions for coagulation and tumor treatment
DE69832628T2 (de) * 1997-04-23 2006-09-07 Instrumentation Laboratory S.P.A. Rekombinant-kaninchengewebefaktor basiertes prothrombinzeitreagenz
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
EP1098665B9 (en) * 1998-07-13 2003-08-13 The Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2727746A1 (en) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
WO2000035887A2 (en) 1998-12-18 2000-06-22 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
RU2159125C1 (ru) * 1999-06-23 2000-11-20 Шахназаров Зурико Шотович Способ лечения гастродуоденальных язв
PL204285B1 (pl) * 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
DE60122750T2 (de) 2000-09-11 2006-12-21 Genentech, Inc., South San Francisco Amidin-Inhibitoren von Serin-Proteasen
US6855509B2 (en) 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
EP1432447A2 (en) * 2001-09-27 2004-06-30 The Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
EP1443954B1 (en) * 2001-10-26 2010-11-24 The Scripps Research Institute Targeted thrombosis by tissue factor polypeptides
BR0309576A (pt) * 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
CA2502162C (en) * 2002-09-30 2014-04-15 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
AU2004221761B2 (en) * 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
DE602004025576D1 (de) * 2003-06-19 2010-04-01 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
WO2007104317A1 (en) * 2006-03-16 2007-09-20 Drugrecure Aps Methods for local treatment with factor vii
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
WO2009097429A1 (en) * 2008-01-29 2009-08-06 Leon Wortham A fast acting primary hemostatic agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456591A (en) * 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
EP0225160B1 (en) * 1985-11-26 1991-08-21 Novo Nordisk A/S Compositions and methods for the treatment of bleeding disorders
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
EP0321526A1 (en) * 1987-06-12 1989-06-28 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of human tissue factor
DE3728491A1 (de) * 1987-08-26 1989-03-09 Heumann Pharma Gmbh & Co Dihydropyridazinon-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Also Published As

Publication number Publication date
JPH07508029A (ja) 1995-09-07
DE69323195T2 (de) 1999-10-14
CA2134750C (en) 2008-01-15
CA2134750A1 (en) 1993-11-25
DK0642352T3 (da) 1999-09-13
ATE175876T1 (de) 1999-02-15
AU4372993A (en) 1993-12-13
EP0642352B1 (en) 1999-01-20
JP3663550B2 (ja) 2005-06-22
AU676168B2 (en) 1997-03-06
WO1993023074A1 (en) 1993-11-25
US5504064A (en) 1996-04-02
EP0642352A1 (en) 1995-03-15
DE69323195D1 (de) 1999-03-04

Similar Documents

Publication Publication Date Title
ES2127286T3 (es) Factor tisular truncado y activador de fviia o fvii para la coagulacion de la sangre.
ES2182899T3 (es) Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii.
ES8505405A1 (es) Un procedimiento para producir un activador de plasminogeno purificado.
ES2167592T3 (es) Preparaciones medicamentosas que contienen un enantiomero de bromuro de ipratropio con duracion de la accion prolongada.
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
ATE273393T1 (de) Modifizierter faktor-vii
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
DE19375061I2 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
ES2035259T3 (es) Compuesto absorbente.
ES2048782T3 (es) Un cuerno usado en un instrumento ultrasonico de intervencion quirurgica.
CO5160272A1 (es) Combinacion de cerivastatina y fibratos
ES2136841T3 (es) Lamina superior con baja rehumectacion y articulo absorbente desechable.
ATE233099T1 (de) Eine formulierung des gerinnungsfaktors viii
SV1995000088A (es) Estructura absorbente elastomerica
EP0583482A4 (en) REMEDY FOR INJURY OR HEMORROIDS.
ES2141534T3 (es) Preparado terapeutico para la aplicacion percutanea de principios activos a traves de la piel.
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
US4721618A (en) Method for controlling bleeding
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
Spaet Analytical review: hemostatic homeostasis
ES8900197A1 (es) Procedimiento para la preparacion de liposomas a partir de una mezcla de un componente lipido y agua
ES2059588T3 (es) Factor xiii para la prevencion de una hemorragia intraventricular.
ES2063747T3 (es) Nuevos benzotiofenos que tienen actividad antialergica, asi como nuevos benzotiofenos y otros benzotiofenos seleccionados que tienen actividad para el tratamiento del sindrome de malestar respiratorio agudo.
US4610880A (en) Composition for controlling hemophilia in mammals

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 642352

Country of ref document: ES